Education
About Us
Working with TipRanks
Follow Us
Veru Inc (VERU)
:VERU
VERU Stock Chart & Stats
$2.44
-$0.01(-1.91%)
At close: 4:00 PM EST
$2.44
-$0.01(-1.91%)
Day’s Range― - ―
52-Week Range$2.11 - $14.20
Previous CloseN/A
Volume1.22M
Average Volume (3M)133.71K
Market Cap
$41.11M
Enterprise Value$73.52M
Total Cash (Recent Filing)$15.01M
Total Debt (Recent Filing)$3.25M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Feb 11, 2026EPS Estimate
-0.33Last Dividend Ex-Date
Apr 28, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding16,058,392
10 Day Avg. Volume90,200
30 Day Avg. Volume133,713
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.21
Price to Sales (P/S)6.14
P/FCF Ratio-4.75
Enterprise Value/Market Cap1.79
Enterprise Value/Revenue11.05
Enterprise Value/Gross Profit28.68
Enterprise Value/Ebitda-2.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.
Potential PartnershipsPositive results from the QUALITY trial could help the company secure a partnership before advancing enobosarm into a pivotal program for the treatment of obesity.
Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.
Bears Say
Market CompetitionThe ease of administration for enobosarm (an oral drug) compares favorably to other competing treatment options that require intravenous administration.
Stock VolatilityA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.
Study ChallengesThe ongoing Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for the treatment of sarcopenic obesity is on track to report topline data in January 2025.
Veru News
VERU FAQ
What was Veru Inc’s price range in the past 12 months?
Veru Inc lowest stock price was $2.11 and its highest was $14.20 in the past 12 months.
What is Veru Inc’s market cap?
Veru Inc’s market cap is $41.11M.
When is Veru Inc’s upcoming earnings report date?
Veru Inc’s upcoming earnings report date is Feb 11, 2026 which is in 59 days.
How were Veru Inc’s earnings last quarter?
Veru Inc released its earnings results on Aug 12, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.534 by $0.034.
Is Veru Inc overvalued?
According to Wall Street analysts Veru Inc’s price is currently Overvalued.
Does Veru Inc pay dividends?
Veru Inc pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru Inc dividends here
What is Veru Inc’s EPS estimate?
Veru Inc’s EPS estimate is -0.33.
How many shares outstanding does Veru Inc have?
Veru Inc has 16,058,392 shares outstanding.
What happened to Veru Inc’s price movement after its last earnings report?
Veru Inc reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.534. Following the earnings report the stock price went down -11.699%.
Which hedge fund is a major shareholder of Veru Inc?
Currently, no hedge funds are holding shares in VERU
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
VERU Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 653.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.50%
12-Months-Change
Fundamentals
Return on Equity
-96.35%
Trailing 12-Months
Asset Growth
-57.71%
Trailing 12-Months
Company Description
Veru Inc
Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of cancer and other serious diseases. The company operates primarily in the oncology and urology sectors, with a portfolio that includes innovative therapies aimed at addressing unmet medical needs in these areas. Veru's core products include its proprietary drug candidates for prostate cancer and other cancers, as well as its medical devices aimed at improving patient outcomes.
VERU Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant positive clinical trial results and a promising regulatory pathway for Inovasarm, which are offset by financial challenges and cash flow concerns. Despite the financial difficulties, the clinical advancements and regulatory progress suggest a positive outlook for the company's drug development efforts.View all VERU earnings summariesTechnical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
Currently, No data available
---